BACKGROUND: Head-to-head comparison studies evaluating the effectiveness and tolerability of anti-TNF drugs in IBD patients are lacking.AIMS: to compare the effectiveness and tolerability of anti-TNF-alpha drugs used in clinical practice in a cohort of patients with moderate to severe UC.METHODS: Retrospectively, 122 UC patients treated with Infliximab (IFX) Originator and Biosimilar, Adalimumab (ADA) and Golimumab (GOL) were included. We performed an ITT analysis to evaluate clinical response and remission, steroid-free clinical remission and endoscopy response according to the different time-points of the follow-up. Baseline and post-induction predictor factors of these outcomes were evaluated using multivariate logistic regressions models. Moreover, a propensity score-based weighting analysis was performed. Data were analyzed using R and STATA11 software.RESULTS: Overall clinical response was 77% after induction, 81.4% at 30 weeks, 76.9% at 52 weeks, while the steroid-free clinical remission was 39.7%, 46%, 54.6%, respectively. After induction, a higher rate of treatment failure was observed in GOL group. At the end of follow-up, lower rates of steroid-free clinical remission and clinical response were obtained by GOL. At week 52, endoscopic response was achieved by 46.5% of the population.CONCLUSIONS: Among the different anti-TNF treatment, moderate-to-severe UC seems to respond better to IFX and ADA, whereas GOL seems to be less effective, despite a similar good safety profile.

REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY

Barberio, Brigida;Zingone, Fabiana;Maccarone, Maria Chiara;Ghisa, Matteo;Massimi, Davide;Lorenzon, Greta;Savarino, Edoardo
2020

Abstract

BACKGROUND: Head-to-head comparison studies evaluating the effectiveness and tolerability of anti-TNF drugs in IBD patients are lacking.AIMS: to compare the effectiveness and tolerability of anti-TNF-alpha drugs used in clinical practice in a cohort of patients with moderate to severe UC.METHODS: Retrospectively, 122 UC patients treated with Infliximab (IFX) Originator and Biosimilar, Adalimumab (ADA) and Golimumab (GOL) were included. We performed an ITT analysis to evaluate clinical response and remission, steroid-free clinical remission and endoscopy response according to the different time-points of the follow-up. Baseline and post-induction predictor factors of these outcomes were evaluated using multivariate logistic regressions models. Moreover, a propensity score-based weighting analysis was performed. Data were analyzed using R and STATA11 software.RESULTS: Overall clinical response was 77% after induction, 81.4% at 30 weeks, 76.9% at 52 weeks, while the steroid-free clinical remission was 39.7%, 46%, 54.6%, respectively. After induction, a higher rate of treatment failure was observed in GOL group. At the end of follow-up, lower rates of steroid-free clinical remission and clinical response were obtained by GOL. At week 52, endoscopic response was achieved by 46.5% of the population.CONCLUSIONS: Among the different anti-TNF treatment, moderate-to-severe UC seems to respond better to IFX and ADA, whereas GOL seems to be less effective, despite a similar good safety profile.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11577/3362923
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 11
social impact